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Abstract The prevalence of bacterial resistance to carbapen-
em antibiotics continues to increase because of bacteria pro-
ducing metallo-β-lactamases (MBL), called carbapenemase-
producing organisms (CPO). Enterobacteriaceae, which can
be a common cause of intra-abdominal infections (IAIs), have
become carbapenem-resistant Enterobacteriaceae (CRE).
Updated international guidelines for the treatment of both IAIs
and IAIs due to CRE have been published. Given the multi-
faceted nature of these infections, these recommendations
have been jointly reviewed and endorsed by the Surgical
Society and the Association of Medical Microbiology and
Infectious Disease. The aims of this review are to summarize
the general and new generation of multimodal procedure to
manage IAIs due to CRE and review the data available on the
combination of interventions to reduce CRE. Future research
should focus on the development of novel and safe antimicro-
bial therapies and the quantification of the incremental effect
of infection control programmes and new methods to rapidly
detect pathogens before patients enter the surgical setting.
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Introduction
Abdominal surgery carries significant morbidity and mortali-
ty, which is in turn associated with an enormous use of health-
care resources. Intra-abdominal infections are particularly sig-
nificant as they occur relatively frequently and have potential-
ly serious consequences; they can slow down patient recovery,
prolong hospital stay, and require greater antibiotic use. Intra-
abdominal infections (IAIs) comprise a wide variety of spe-
cific infections, ranging from uncomplicated appendicitis to
cholecystitis and faecal peritonitis, and are therefore classified
as either uncomplicated or complicated such as intra-
abdominal abscess or peritonitis. In the majority of uncompli-
cated IAIs, definitive management is surgical and antibiotics
are not warranted beyond prophylaxis of the incision against
SSI. However, in certain instances, the pathogens extend
beyond the source organ and into the peritoneal cavity through
a perforated viscus, thereby stimulating the systemic inflam-
matory response to a greater degree. The extent of such
infection depends upon the combination of local host defences
and the virulence of microorganisms [1].
Pyogenic liver abscesses usually develop following perito-
nitis due to an intra-abdominal abscess that subsequently
spreads to the liver via the portal circulation or via direct
spread from a biliary infection. They may also result from
arterial haematogenous seeding in the setting of a systemic
infection.
In such cases, sepsis is a serious complication and
mortality is approximately 25–35 % [1–3, 4•] but may
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exceed 80 % if the infection is caused by multidrug-
resistant (MDR) microorganisms [5••, 6•, 7–9].
The management of patients with MDR infections often
requires the involvement of multiple medical disciplines. In-
adequate surgical source control of an intra-abdominal infec-
tion with lack of control of the underlying pathological pro-
cess by resection, closure or drainage, or drainage of existing
purulent collections are causes of therapeutic failure. Selection
of an ineffective antimicrobial agent is another cause of
therapeutic failure [7, 8, 10].
Resistance to carbapenems has been described as naturally
occurring in several Gram-positive and Gram-negative bacte-
rial species producing metallo-β-lactamases (MBL). This
phenotypic grouping of enzymes confers resistance to all β-
lactams except monobactams and is not susceptible to the
clinically available β-lactamase inhibitors.
Several types of these enzymes have been detected, namely
IMP, VIM, SPM, GIM, and SIM, mostly in Pseudomonas
aeruginosa and other Gram-negative nonfermenters [11••,
12]. Moreover, the two VIM-producing Enterobacteriaceae
identified in the USA were the same strains isolated from
patients previously hospitalized in other southern European
countries such as Greece and Italy [13–15].
Carbapenem-Resistant Enterobacteriaceae
Enterobacteriaceae are the predominant microbial species of
bacterial flora in the human gut and also a frequent cause of
IAIs. Therefore, the increased resistance among the
Enterobacteriaceae to antimicrobial agents has resulted in
the increasing frequency of IAIs caused by MDR strains [10,
16]. As a result, restricting more and more the treatment
options and the more frequent use of broad-spectrum carba-
penem agents as a last chance for effective therapy have
inevitably resulted in the emergence and spread of
carbapenem-resistant Enterobacteriaceae (CRE), and this
has become a serious public health problem over the past
decade.
Enterobacteriaceae can be resistant to carbapenems by
mechanisms other than a carbapenemase, the most common
of which is expression of an extended-spectrum
cephalosporinase, such as an AmpC-type enzyme or an
extended-spectrum beta-lactamase (ESBL), combined with
porin loss. Of major concern is the coexistence of multiple
ESBL and carbapenemase genes as well as that of other
antibiotic resistance determinants on mobile elements that,
along with the genetic plasticity of the Enterobacteriaceae,
has led to rampant intra- and interspecies transfer of these
elements and emergence of organisms with resistance to vir-
tually all antibiotics [17, 18].
Among CRE, virulent clones of Klebsiella pneumoniae in
particular have been described as an emerging causative agent
of complicated intra-abdominal infections such as liver or
pancreatic abscesses [19, 20]. Carbapenem resistance in
K. pneumoniae can be mediated by the production of
carbapenemases belonging to Ambler class A, B, or D. The
most common carbapenemase worldwide is K. pneumoniae
carbapenemase (KPC), an Ambler molecular class A enzyme
that hydrolyses a broad variety of β-lactams. In addition,
KPC-producing isolates demonstrate resistance to many
agents commonly used to treat Gram-negative infections,
including quinolones, and aminoglycosides. The globally dis-
tributed sequence type (ST) ofK. pneumoniae associated with
KPC enzyme production is ST258. However, despite the
internationally prominent role of ST258, other K. pneumoniae
STs reported as carrying KPC include STs 14, 21, 37, 45, 101,
228, 234, 257, and 259 in the USA and STs 277, 327,
340, and 376 in Israel. The potential for the spread of
plasmid-encoded KPC carbapenemases to different
strains, including those locally more prevalent, is a
serious cause of concern [9, 21–23].
Management of Intra-abdominal Infections due to CRE
General Recommendations
Many strategies have been developed to manage intra-
abdominal infections due to CRE [24, 25]. Given the multi-
faceted nature of these infections, recommendations have
been jointly developed and endorsed by the Surgical Society
and the Association of Medical Microbiology and Infectious
Disease. However, no guideline can take into account all the
variations in ecology, patterns of antimicrobial resistance,
patient characteristics, and organizational models of health
care in different countries.
Antimicrobial therapy should be initiated once a patient
receives a diagnosis of an intra-abdominal infection or once
such an infection is considered likely. For patients with septic
shock, antibiotics should be administered as soon as possible.
Antimicrobial therapy strictly depends upon monitoring
in vitro antimicrobial susceptibility using the clinical
breakpoints defined by the CLSI guidelines for the
detection of isolates producing carbapenemases [26]
and the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) [27].
Until now, the detection of carbapenemase production has
been complicated because some carbapenemase-producing
isolates demonstrate elevated but susceptible carbapenem
MICs. In fact, variability in the performance of phenotypic
tests for detection of MBLs and difficulty with their interpre-
tation have been described previously [28], and our reports
demonstrate the need to include multiple methods to ensure
reliable detection of MBLs. The Etest is a feasible option, but
MBL could demonstrate only a subtle deformation of the
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ellipse in the K. pneumoniae parent and Escherichia coli
transformant strains [29].
Specific Antimicrobial Treatment
Colistin and tigecycline have recently been granted a major
role in the treatment of the most problematic MDR Gram-
negative pathogens (ESBL- and carbapenemase-producing
strains). The progressive increase of these pathogens has
called for a re-evaluation of old antimicrobials such as
fosfomycin, doxycycline, and chloramphenicol and new
drugs such as temocillin [30, 31]. Investigation on their activ-
ity against CRE showed a good activity against individual
isolates [32–34] but rarely a bactericidal effect against
carbapenemase-producing K. pneumoniae for which a double
or triple combination of antibiotics is suggested [35].
Previous studies have reported them being used as a mono-
therapy for patients with serious polymicrobial infections,
including MDRmicroorganisms [20, 30, 36]. Both antibiotics
show favourable penetration into various tissues, such as the
sites of infection and soft tissues of the skin, as well as intra-
abdominal infections (official indications). A review of cur-
rent literature [21] concludes that clinical success rates are low
when polymyxins (e.g. colistin) are used as monotherapy but
higher when they are used in combination with tigecycline or
gentamicin [21]. Accordingly, combined tigecycline and co-
listin has shown good in vitro synergy against carbapenem-
resistant Acinetobacter baumannii with a high-level
imipenem resistance [37].
In our study [9], we report on the use of high-dose tigecyc-
line in patients with intra-abdominal abscess due to
carbapenemase-producing K. pneumoniae, especially in those
with a less favourable clinical course and with KPC isolates
showing MICs of tigecycline near the upper limit of the
EUCAST susceptibility range (http://www.eucast.org). [27]
In addition, the role of combination therapy, including
carbapenem-containing regimens investigated by in vitro
time-kill experiments, remains to be defined [38]. The main
therapeutic strategies cited in the literature for CRE infection
clinical management are reported in Table 1.
Current Practice Procedures for the Management
of Intra-abdominal Infections due to CRE
Selective decontamination of the digestive tract (SDD) re-
duces the number of Gram-negative and yeast infections in
intensive care patients and reduces hospital mortality [52, 53].
It does so by eradicating Gram-negative bacteria and yeasts
from the intestinal tract, while preserving Gram-positive and
anaerobic bacteria. Treatment consists of the local application
of tobramycin, polymyxin, and amphotericin in the orophar-
ynx and gastrointestinal tract. If the gut barrier is intact, the
antibiotics exert their effect in the digestive tract and are not
absorbed. However, conditions such as sepsis, shock, and
major surgery can lead to gut barrier failure [54] and may
result in the antibiotics leaking from the gut into the blood.
Experience with known antibiotic classes provides
established benchmarks for new class members. The next-
generation aminoglycoside plazomicin retains activity against
all isolates of K. pneumoniae, E. coli, and Enterobacter spp.
tested, including those with ESBL, KPC, and VIM-MBL re-
sistance mechanisms, and may represent a promising alterna-
tive for the treatment of MDR pathogens. Pharmacokinetic and
pharmacodynamic studies in animal models and in healthy
volunteers have been started, and a pivotal phase 3 superiority
trial of plazomicin for the treatment of serious CRE infections
will be initiated in the first quarter of 2014 [55, 56].
New inhibitors of topoisomerases, cell wall synthesis, and
protein synthesis are currently being developed. At this mo-
ment, in vitro and animal model studies have shown that they
are well tolerated in animals and efficacious in Gram-negative
infection models [57, 58].
Finally, the monoclonal antibody (mAb) revolution offers
many new options for the treatment of infectious diseases,
though it is the subject of ongoing debate for various reasons,
including the high cost of immunoglobulin preparations and
relatively small markets. Clinical trials using mAb therapies
are currently limited to treating Gram-positive bacteria and
yeast infections [59, 60]. In this framework, nanotechnology-
based solutions and, in particular, silver nanoparticles
(AgNPs) have recently emerged as promising new antibacte-
rial agents in the market [61•].
Key Recommendations for Infection Control and Prevention
CRE infections mostly occur in intensive care units and
chronic care facilities. Transmission of carbapenem-resistant
genes among bacterial species existing in the same environ-
ment contributes to the spread of resistance. Infection control
and antibiotic stewardship remain our main lines of defence to
limit propagation [62••].
When CRE infections occur, they must be reported without
delay and an investigation to determine the source initiated by
a team of epidemiologists. Moreover, infection control staff
should perform active surveillance screening, collecting rectal
swabs from all the patients in units where microorganisms
have been identified. The health-care personnel should also be
instructed to screen and isolate patients with multidrug-
resistant organisms, as recommended by the Centers for Dis-
ease Control and Prevention (Atlanta).
Infection control measures should include strict contact
precautions and more intensive cleaning practices. Standard
infection control practices involve basic hand hygiene before
and after unit entry with appropriate antimicrobial soaps; an
aseptic technique when performing invasive procedures; the
use of a gown, gloves, and mask for sterile procedures; routine
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environmental cleaning and disinfection; and antibiotic stew-
ardship. Flags indicating the presence of a multidrug-resistant
organism should be placed in the electronic medical record
and chart.
Table 1 Antibiotic treatment indications for clinical management of CRE infection
Monotherapy Combination therapy Reference Flag
Colistin
3 MU every 8 h,
loading dose of 6–9 MU,
followed by maintenance
doses of 4.5–6 MU every
12 h—always adjusting to
renal function
Poulakou G et al., [37]
Daikos GL et al. [39]
Kontopidou F et al. [40]
Colistin remains a valuable antimicrobial agent for treating
these infections.
Colistin+tigecycline Hirsch EB et al. [21],
Sheng et al. [38]
Tigecycline plus gentamicin or colistin was effective for
treating 24 of 26 (92 %) Klebsiella pneumoniae
carbapenemase-producing K. pneumoniae infectious




Gaibani P et al. [42]
A. baumannii infection mortality is not reduced by addition of
rifampicin to colistin.
Combinations of colistin plus rifampicin, and less frequently
tigecycline, exhibited synergistic activity in vitro against
colistin-resistant KPC-Kp strains.
Colistin+carbapenem Peck KR et al. [32]
Akova M et al. [43]
In cases where the MICs for carbapenems are not available or
are higher than 8 mg/l, this class of drugs should not be
used as part of a combination regimen to avoid further
selection of resistance.
Colistin+aminoglycosides Hirsch EB et al. [21] Treatment with aminoglycosides polymyxin combinations
have higher success rates compared to polymyxin
monotherapy.
Colistin+fosfomycin Corvec S et al. [44] The combination of fosfomycin plus colistin showed the




Tängdén T et al. [35] Inmultivariate analysis, combination therapywith tigecycline,
colistin, and meropenem was independently associated
with survival.
Tigecycline,
100 mg IV loading, then
50 mg IV q12 h,
200 mg IV loading, then
100 mg IV q12 h
Bodmann KF et al. [45]
Di Carlo P et al. [9]
Trials with higher dosing schedules are eagerly awaited;
favourable clinical success rates in a population of patients
seriously ill with complicated intra-abdominal infections or
complicated skin and skin tissue infections.
Fosfomycin
daily dose ranges from 12 to
16 g on average,
administered in 2–4 infusions
a dosing interval of 6–8 h
should be preferred over 12 h
In Europe, tromethamine
derivative and fosfomycin
calcium for oral use,
as well as fosfomycin
disodium for intravenous
use, are available and
marketed under different
brand names.
Michalopoulos AS et al.
[46]
Falagas ME et al. [47]
Fosfomycin should not be used as monotherapy to treat CRE
infection for potential emergence of resistance during therapy.
Aminoglycosides
Amikacin 1,500–2,000 mg/
day every 24 h
Gentamicin 7 mg/kg/day
every 24 h
Levy Hara G et al. [48] Typically, nephrotoxicity related to aminoglycoside use is
reversible. Aminoglycosides should not be used as
monotherapy to treat CRE infection especially asmonotherapy
against carbapenemase-producing K. pneumoniae.
Tetracycline
100 mg q12 h (maximum
dose 300 mg)
Livermore DM et al.
[49]
Merino M et al. [50]
Carbapenem-resistant Enterobacteriaceae and, recently,
outbreak of carbapenem-resistant Acinetobacter baumannii
isolates showed susceptibility to minocycline.
Chloramphenicol
50 mg/kg/day in 4 divided
doses increased to
100 mg/kg/day for severe
infections
Livermore DM et al.
[49]
Cuzon G et al. [51]
Carbapenem-resistant Enterobacteriaceae and, recently,
outbreak of E. coli producing novel NDM carbapenemase
showed susceptibility to minocycline.
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Enhanced infection control practices include active surveil-
lance (non-clinical) cultures of patients, staff, and the care
environment, performed once or repeated at regular intervals,
to detect asymptomatic carriage; geographic (spatial)
cohorting of patients; geographic cohorting of staff; contact
precautions (wearing a gown and gloves when entering the
patient care area); dedicated patient equipment (i.e.
glucometers and stethoscopes); un-identified unit observa-
tions of infection control practices; staff education; and regu-
lar consultation with infectious disease specialists. Addition-
ally, in some centres, the use of periodic screening surveil-
lance cultures has been recommended to better detect poten-
tially unrecognized sources or reservoirs of resistant patho-
gens in the surgical setting.
The clinician’s best strategy to manage nosocomial
infections caused by CRE is to prevent infection or
colonization of these organisms. A multifaceted ap-
proach to the treatment and management of these or-
ganisms when they are identified is needed, including
strict adherence to enhanced infection control practices;
active surveillance cultures of patients, staff, and the
environment; and rapid switch to appropriate antimicro-
bial therapy upon receipt of the offending pathogen’s
antimicrobial susceptibility report, in order to better
target therapy.
In Fig. 1 are shown the “Routine Practices and Ad-
ditional Precautions in All Health Care Settings” report-
ed by the Ontario Agency for Health Protection and
Promotion, Provincial Infectious Diseases Advisory
Committee [63].
Future research should focus on the development of novel
and safe antimicrobial therapies which are active against CRE
infections, evidence-based infection control practices, and
new methods to rapidly detect pathogens before patients enter
the surgical setting.
Expert Opinion
Recent epidemiological studies have shown the following:
& Owing to the limitation in efficacy and potential for tox-
icity of the alternative agents, many experts recommend
using combination therapy instead of monotherapy in CR-
KP-infected patients. Nevertheless, in the absence of well-
designed comparative studies, the best combination to
manage CRE infection, the continued role for carbapen-
ems in combination therapy, and when combination ther-
apy should be started, remain open questions.
& A lower-than-expected rate of health-care-associated in-
fections based on estimates in other countries, due to a
number of factors: diagnostic accuracy problems, differ-
ences in hospital patient case-mix, unsatisfactory surveil-
lance system sensitivity, and incomplete and untimely
reports.
& A very high frequency of infections in surgical patients
especially in cancer patients; nevertheless, studies on in-
fection control measures have shown that their incidence
declines when control programmes are implemented.
& Preoperative markers of infection complications are im-
portant in high-risk populations such as older patients,
because of frailty, disability, and co-morbidity.
& Decontamination to eradicate MDR-GNB should only be
used in research settings and with detailed and real-time
microbiological monitoring.
There are five ways to control multiresistant bacteria in
your hospital setting:
& Prevent understaffing of nurses.
& Clean the skin.
& Screen and isolate.
Fig. 1 “Routine Practices and
Additional Precautions in All
Health Care Settings” (reported




Curr Infect Dis Rep (2014) 16:428 Page 5 of 8, 428
& Clean the environment.
& Limit unnecessary antibiotic use.
Conclusions
Intra-abdominal infections are particularly significant as they
occur relatively frequently and have potentially serious con-
sequences; they can slow down patient recovery, prolong
hospital stay, and entail greater antibiotic use.
The management of patients with these infections often
demands the involvement of multiple medical disciplines.
Complicated infections are those that require both surgical
or radiological drainage procedures and antimicrobial therapy.
Inadequate surgical source control of an intra-abdominal in-
fection with lack of control of the underlying pathological
process by resection, closure or drainage, or drainage of
existing purulent collections, are causes of therapeutic failure.
Selection of an ineffective antimicrobial agent is another cause
of therapeutic failure.
Our ability to prevent significant morbidity and mortality
from intra-abdominal infections due to CRE remains a
challenge.
Although antimicrobial prophylaxis has been shown to be
effective in selected patient populations, there is still some
debate on the application of risk prediction tools and other
preventive strategies. There is a continued need for surveil-
lance of CRE in order to develop and evaluate prevention
strategies and to monitor changes in incidence and resistance.
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